Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension
NCT ID: NCT06249633
Last Updated: 2024-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
EARLY_PHASE1
20 participants
INTERVENTIONAL
2024-02-29
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nitric Oxide Administration for Acute Respiratory Distress Syndrome
NCT00240487
Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia
NCT03576885
Inhaled Nitric Oxide (INO) In Hypoxic Respiratory Failure
NCT00922532
Inhaled Nitric Oxide by Oxygen Hood in Neonates
NCT00732537
Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants
NCT01748045
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
iNOMAX
Nitric Oxide
Inhaled nitric oxide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nitric Oxide
Inhaled nitric oxide
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mechanically ventilated
* Age ≥ 18 years
Exclusion Criteria
* History of more than mild pulmonary hypertension preceding ARDS diagnosis
* Presence of pre-existing significant valvular disease
* Presence of pre-existing left ventricular dysfunction or significant hypertrophy
* Consent cannot be obtained from the patient or his/her surrogates
* Refusal of consent
* Opinion of treating physicians that enrolling the patient in the study would be detrimental to his/her outcome
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mallinckrodt
INDUSTRY
Yuri Matusov
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yuri Matusov
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuri Matusov, MD
Role: PRINCIPAL_INVESTIGATOR
Cedars-Sinai Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cedars-Sinai Medical Center
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00001807
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.